Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 1/2012

01-01-2012 | Original paper

Factors associated with mortality after breast cancer metastasis

Authors: Su Yon Jung, Margaret Rosenzweig, Susan M. Sereika, Faina Linkov, Adam Brufsky, Joel L. Weissfeld

Published in: Cancer Causes & Control | Issue 1/2012

Login to get access

Abstract

Background

It is generally accepted that patients with breast cancer metastases have very poor survival. Metastatic breast cancer patients can be considered a heterogeneous population with a varied clinical course, which underscores the need for accurate prediction of survival based on prognostic factors. The purpose of the present study was to identify factors related to survival in breast cancer patients after diagnosis with metastatic disease.

Populations and methods

A total of 557 patients with breast cancer metastasis diagnosis seen at one large urban practice have been followed up between 1 January, 1999 and 30 June, 2010. Demographic, tumor characteristics, clinical factors as predictors of survival were analyzed using log-rank test and Cox regression model.

Results

The median survival length was 39 months (range 1–138 months) with 154 (27.7%) alive and 403 (72.3%) dead at the end of follow-up period. This study demonstrated that a history of hypertension, ER/PR status, HER2 status, metastasis-free interval, metastatic location (including brain, bone and liver), and BMI at diagnosis with metastatic breast cancer were the most relevant prognostic factors for survival after metastatic disease diagnosis.

Conclusion

Findings of this study may form a foundation for the growing corpus of knowledge explaining the outcome differences in treatment of patients with metastatic breast cancer, potentially helping to create tailored counseling and personalized treatment approaches for this vulnerable group.
Literature
1.
Surveillance Epidemiology and End Results Program (SEER). SEER Stat Database: SEER Stat Fact Sheets; 2008
2.
3.
Henderson IC, Harris JR, Kinne DW (1989) Cancer of the breast. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer principles & practice of oncology, 3rd edn. Lippincott, Philadelphia, pp 1197–1268
4.
Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97(3):545–553PubMedCrossRef
5.
Largillier R, Ferrero JM, Doyen J et al (2008) Prognostic factors in 1, 038 women with metastatic breast cancer. Ann Oncol 19(12):2012–2019PubMedCrossRef
6.
Beslija S, Bonneterre J, Burstein HJ et al (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20(11):1771–1785PubMedCrossRef
7.
Vincent MD, Powles TJ, Skeet R et al (1986) An analysis of possible prognostic features of long term and short term survivors of metastatic breast cancer. Eur J Cancer Clin Oncol 22(9):1059–1065PubMedCrossRef
8.
Hortobagyi GN, Smith TL, Legha SS et al (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1(12):776–786PubMed
9.
Cluze C, Colonna M, Remontet L et al (2009) Analysis of the effect of age on the prognosis of breast cancer. Breast Cancer Res Treat 117(1):121–129PubMedCrossRef
10.
Grau AM, Ata A, Foster L et al (2005) Effect of race on long-term survival of breast cancer patients: transinstitutional analysis from an inner city hospital and university medical center. Am Surg 71(2):164–170PubMed
11.
Bradley CJ, Given CW, Roberts C (2002) Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94(7):490–496PubMed
12.
Lagerlund M, Bellocco R, Karlsson P, Tejler G, Lambe M (2005) Socio-economic factors and breast cancer survival—a population-based cohort study (Sweden). Cancer Causes Control 16(4):419–430PubMedCrossRef
13.
Dalton SO, During M, Ross L et al (2006) The relation between socioeconomic and demographic factors and tumour stage in women diagnosed with breast cancer in Denmark, 1983–1999. Br J Cancer 95(5):653–659PubMedCrossRef
14.
Rezaianzadeh A, Peacock J, Reidpath D, Talei A, Hosseini SV, Mehrabani D (2009) Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran. BMC Cancer 9:168PubMedCrossRef
15.
Bouchardy C, Verkooijen HM, Fioretta G (2006) Social class is an important and independent prognostic factor of breast cancer mortality. Int J Cancer 119(5):1145–1151PubMedCrossRef
16.
Tao MH, Shu XO, Ruan ZX, Gao YT, Zheng W (2006) Association of overweight with breast cancer survival. Am J Epidemiol 163(2):101–107PubMedCrossRef
17.
Caan BJ, Kwan ML, Hartzell G et al (2008) Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes Control 19(10):1319–1328PubMedCrossRef
18.
Berclaz G, Li S, Price KN et al (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 15(6):875–884PubMedCrossRef
19.
Loi S, Milne RL, Friedlander ML et al (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14(7):1686–1691PubMedCrossRef
20.
Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA (2005) Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 14(8):2009–2014PubMedCrossRef
21.
West DW, Satariano WA, Ragland DR, Hiatt RA (1996) Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol 6(5):413–419PubMedCrossRef
22.
Nagel G, Wedding U, Rohrig B, Katenkamp D (2004) The impact of comorbidity on the survival of postmenopausal women with breast cancer. J Cancer Res Clin Oncol 130(11):664–670PubMedCrossRef
23.
Cronin-Fenton DP, Norgaard M, Jacobsen J et al (2007) Comorbidity and survival of Danish breast cancer patients from 1995 to 2005. Br J Cancer 96(9):1462–1468PubMed
24.
Gordon NH, Silverman P, Lasheen W, Meinert J, Siminoff LA (2007) Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer. Breast Cancer Res Treat 102(3):301–312PubMedCrossRef
25.
Braithwaite D, Tammemagi CM, Moore DH et al (2009) Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer 124(5):1213–1219PubMedCrossRef
26.
Ahern TP, Lash TL, Thwin SS, Silliman RA (2009) Impact of acquired comorbidities on all-cause mortality rates among older breast cancer survivors. Med Care 47(1):73–79PubMedCrossRef
27.
Ruiterkamp J, Ernst MF, van de Poll-Franse LV, Bosscha K, Tjan-Heijnen VC, Voogd AC (2009) Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol 35(11):1146–1151PubMedCrossRef
28.
Census 2000 summary file 3 (SF 3): U.S. Census Bureau; 2000
29.
30.
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef
31.
Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619PubMedCrossRef
32.
Dempster AP, Laird NM, Rubin DB (1977) Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc Ser B (Methodological) 39(1):1–38
33.
Hosmer DW Jr, Lemeshow S (1999) Applied survival analysis. Wiley Interscience, London
34.
Swenerton KD, Legha SS, Smith T et al (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39(5):1552–1562PubMed
35.
Falkson G, Gelman R, Falkson CI, Glick J, Harris J (1991) Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J Clin Oncol 9(12):2153–2161PubMed
36.
Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J (1999) Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 56(1):67–78PubMedCrossRef
37.
Cutler SJ, Ardyce JA, Taylor SG III (1969) Classification of patients with disseminated cancer of the breast. Cancer 24(5):861–869PubMedCrossRef
38.
Ryberg M, Nielsen D, Osterlind K, Skovsgaard T, Dombernowsky P (2001) Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol 12(1):81–87PubMedCrossRef
39.
Robain M, Pierga JY, Jouve M et al (2000) Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer. Eur J Cancer 36(18):2301–2312PubMedCrossRef
40.
Andre F, Slimane K, Bachelot T et al (2004) Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22(16):3302–3308PubMedCrossRef
41.
Yamamoto N, Watanabe T, Katsumata N et al (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16(7):2401–2408PubMed
42.
Vogel CL, Azevedo S, Hilsenbeck S, East DR, Ayub J (1992) Survival after first recurrence of breast cancer The Miami experience. Cancer 70(1):129–135PubMedCrossRef
43.
Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59(3):271–278PubMedCrossRef
44.
Goldhirsch A, Gelber RD, Castiglione M (1988) Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol 6(1):89–97PubMed
45.
Hortobagyi GN, Kau S-W, Buzdar AU, et al. (2004) What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? [Abstract]. J Clin Oncol, In: ASCO annual meeting proceedings (Post-Meeting Edition), vol 22(14S, July 15 Supplement), p 585
46.
Grasic-Kuhar C, Bracko M, Zakotnik B (2008) Risk factors for late relapse and death in patients with early breast cancer. Neoplasma 55(5):416–420PubMed
47.
EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717
48.
Hamet P (1996) Cancer and hypertension. An unresolved issue. Hypertension 28(3):321–324PubMed
Metadata
Title
Factors associated with mortality after breast cancer metastasis
Authors
Su Yon Jung
Margaret Rosenzweig
Susan M. Sereika
Faina Linkov
Adam Brufsky
Joel L. Weissfeld
Publication date
01-01-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 1/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9859-8

Other articles of this Issue 1/2012

Cancer Causes & Control 1/2012 Go to the issue

Original paper

Pathways to the diagnosis of thyroid cancer in New South Wales: a population-based cross-sectional study

Original paper

Pesticide exposure in farming and forestry and the risk of uveal melanoma

Original paper

Cholecystectomy and risk of pancreatic cancer: a meta-analysis of observational studies

Original paper

Occupational risks and lung cancer burden for Chinese men: a population-based case–referent study

Original paper

Mammography capacity and appointment wait times: barriers to breast cancer screening

Original paper

Dual effect of short interval between first and second birth on ductal breast cancer risk in Finland
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits